Literature DB >> 31953473

An implantable system for long-term assessment of atrial fibrillation substrate in unanesthetized rats exposed to underlying pathological conditions.

Hadar Klapper-Goldstein1,2, Michael Murninkas3,4, Roni Gillis3,4, Wesam Mulla3,4, Eran Levanon3,4, Sigal Elyagon3,4, Ronen Schuster5, Dor Danan6, Hagit Cohen6, Yoram Etzion7,8.   

Abstract

Atrial fibrillation (AF) is a progressive arrhythmia with underlying mechanisms that are not fully elucidated, partially due to lack of reliable and affordable animal models. Here, we introduce a system for long-term assessment of AF susceptibility (substrate) in ambulatory rats implanted with miniature electrodes on the atrium. Rats were subjected to excessive aldosterone (Aldo) or solvent only (Sham). An additional group was exposed to myocardial infarction (MI). AF substrate was tested two- and four-weeks post implantation and was also compared with implanted rats early post-implantation (Base). Aldo and MI increased the AF substrate and atrial fibrosis. In the MI group only, AF duration was correlated with the level of atrial fibrosis and was inversely correlated with systolic function. Unexpectedly, Shams also developed progressive AF substrate relative to Base individuals. Further studies indicated that serum inflammatory markers (IL-6, TNF-alpha) were not elevated in the shams. In addition, we excluded anxiety\depression due to social-isolation as an AF promoting factor. Finally, enhanced biocompatibility of the atrial electrode did not inhibit the gradual development of AF substrate over a testing period of up to 8 weeks. Overall, we successfully validated the first system for long-term AF substrate testing in ambulatory rats.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31953473      PMCID: PMC6969190          DOI: 10.1038/s41598-020-57528-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  39 in total

Review 1.  Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications.

Authors:  Mikhail S Dzeshka; Gregory Y H Lip; Viktor Snezhitskiy; Eduard Shantsila
Journal:  J Am Coll Cardiol       Date:  2015-08-25       Impact factor: 24.094

Review 2.  Modifiable Risk Factors and Atrial Fibrillation.

Authors:  Dennis H Lau; Stanley Nattel; Jonathan M Kalman; Prashanthan Sanders
Journal:  Circulation       Date:  2017-08-08       Impact factor: 29.690

3.  Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts.

Authors:  Stéphanie C M Choisy; Lesley A Arberry; Jules C Hancox; Andrew F James
Journal:  Hypertension       Date:  2007-01-22       Impact factor: 10.190

Review 4.  Mechanisms of atrial fibrillation: lessons from animal models.

Authors:  Stanley Nattel; Akiko Shiroshita-Takeshita; Bianca J J M Brundel; Léna Rivard
Journal:  Prog Cardiovasc Dis       Date:  2005 Jul-Aug       Impact factor: 8.194

Review 5.  Novel molecular targets for atrial fibrillation therapy.

Authors:  Dobromir Dobrev; Leif Carlsson; Stanley Nattel
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

6.  Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.

Authors:  M Haïssaguerre; P Jaïs; D C Shah; A Takahashi; M Hocini; G Quiniou; S Garrigue; A Le Mouroux; P Le Métayer; J Clémenty
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

7.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

Review 8.  The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis.

Authors:  Jordi Heijman; Vincent Algalarrondo; Niels Voigt; Jonathan Melka; Xander H T Wehrens; Dobromir Dobrev; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2015-12-23       Impact factor: 10.787

9.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; Deirdre A M van der Kuip; Albert Hofman; Jan A Kors; Gerard van Herpen; Bruno H Ch Stricker; Theo Stijnen; Gregory Y H Lip; Jacqueline C M Witteman
Journal:  Eur Heart J       Date:  2006-03-09       Impact factor: 29.983

10.  Lone Atrial Fibrillation Is Associated With Impaired Left Ventricular Energetics That Persists Despite Successful Catheter Ablation.

Authors:  Rohan S Wijesurendra; Alexander Liu; Christian Eichhorn; Rina Ariga; Eylem Levelt; William T Clarke; Christopher T Rodgers; Theodoros D Karamitsos; Yaver Bashir; Matthew Ginks; Kim Rajappan; Tim Betts; Vanessa M Ferreira; Stefan Neubauer; Barbara Casadei
Journal:  Circulation       Date:  2016-09-14       Impact factor: 29.690

View more
  4 in total

1.  VDAC1 in the diseased myocardium and the effect of VDAC1-interacting compound on atrial fibrosis induced by hyperaldosteronism.

Authors:  Hadar Klapper-Goldstein; Ankit Verma; Sigal Elyagon; Roni Gillis; Michael Murninkas; Srinivas Pittala; Avijit Paul; Varda Shoshan-Barmatz; Yoram Etzion
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

2.  Cannabinoid Receptor Agonist Inhibits Atrial Electrical Remodeling in a Tachypaced Ex Vivo Rat Model.

Authors:  Danielle I Lee; Michael Murninkas; Sigal Elyagon; Yoram Etzion; Hope D Anderson
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 3.  Research Progress of Myocardial Fibrosis and Atrial Fibrillation.

Authors:  Guangling Li; Jing Yang; Demei Zhang; Xiaomei Wang; Jingjing Han; Xueya Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-25

4.  Is PTSD-Phenotype Associated with HPA-Axis Sensitivity? Feedback Inhibition and Other Modulating Factors of Glucocorticoid Signaling Dynamics.

Authors:  Dor Danan; Doron Todder; Joseph Zohar; Hagit Cohen
Journal:  Int J Mol Sci       Date:  2021-06-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.